RxDoctor Payments Data

Edward Laub, MD

Internal Medicine · Trenton, NJNPI 1215974902

Payments from drug & device makers

$38,746in general payments, 2019–2025

Across 1,585 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • AstraZeneca$6K
  • Amgen$3K
  • Boehringer Ingelheim$2K
  • Novo Nordisk$2K
  • GSK$2K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$6552%
  • Speaking & faculty fees$3,1308%
  • Food & beverage$33,30486%
  • Education$120%
  • Gifts$1,6454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)250$6,961
AstraZeneca117$5,605
Amgen(2 entities)151$3,389
Boehringer Ingelheim104$2,356
Novo Nordisk138$1,978
GSK88$1,742
Johnson & Johnson(2 entities)55$1,706
Lilly USA, LLC99$1,701
Sekisui Diagnostics LLC2$1,645
Kowa Pharmaceuticals America, Inc.123$1,628
Bayer60$1,300
Amarin Pharma, Inc.59$1,052
Phathom Pharmaceuticals, Inc.15$820
Paratek Pharmaceuticals, Inc.47$778
Abbott18$547
Pfizer25$533
Axsome Therapeutics, Inc.15$505
Esperion Therapeutics, Inc.27$384
Novo Nordisk AS1$355
Sanofi-aventis U.S. LLC14$313
Astellas Pharma US Inc13$297
Merck17$236
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$230
Novartis15$225
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$204
Vanda Pharmaceuticals Inc.15$197
Teva Pharmaceuticals USA, Inc.4$195
Avanir Pharmaceuticals, Inc.5$182
Nestle Healthcare Nutrition Inc.9$181
Eisai Inc.10$144
Boston Scientific3$117
Sanofi1$110
Exact Sciences6$106
Otsuka America Pharmaceutical, Inc.1$101
Quidel Corporation1$92
Takeda Pharmaceuticals U.S.A., Inc.7$86
Daiichi Sankyo Inc.6$84
Aimmune Therapeutics, Inc.4$73
Si-bone, Inc.2$68
Arbor Pharmaceuticals, Inc.4$68
Philips North America LLC3$51
Ardelyx, Inc.2$42
Edwards Lifesciences2$36
Globus Medical1$33
Coloplast1$32
Vifor Pharma, Inc.2$31
Cleerly, Inc.1$23
Lundbeck LLC1$20
Ionis Pharmaceuticals, Inc.1$17
Modernatx, Inc.1$17
Biogen1$17
Radius Health, Inc.1$15
Corium, LLC1$15
Medicure Pharma Inc.1$15
Biohaven Pharmaceutical Holding Company Ltd.1$14
Bausch Health US, LLC1$13
Azurity Pharmaceuticals, Inc.1$13
Eyevance Pharmaceuticals LLC1$13
Hikma Pharmaceuticals USA1$13
Regeneron Healthcare Solutions, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,746 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$108,539
Medicare patients
109
Services billed
1,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol175$155,533
KerendiaFinerenone134$139,071
JardianceEmpagliflozin117$114,635
CreonLipase/Protease/Amylase33$92,404
RybelsusSemaglutide77$71,666
Repatha SureclickEvolocumab77$67,781
Icosapent Ethyl145$64,538
ProliaDenosumab36$62,110
XareltoRivaroxaban56$60,229
OtezlaApremilast16$46,814
Xigduo XrDapaglifloz Propaned/Metformin43$33,721
VraylarCariprazine Hcl20$30,123
Tresiba Flextouch U-200Insulin Degludec23$29,531
OzempicSemaglutide21$29,442
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$27,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$5,605$183,466216 claims
AbbVieCreon, Vraylar, Linzess, Qulipta, Synthroid$6,961$156,542105 claims
BayerKerendia$1,300$139,071134 claims
Boehringer IngelheimJardiance, Synjardy$2,356$129,654139 claims
AmgenProlia, Otezla$3,389$108,92452 claims
Novo NordiskRybelsus, Ozempic$1,978$101,10898 claims
Johnson & JohnsonXarelto$1,706$60,22956 claims
Lilly USA, LLCTrulicity, Mounjaro$1,701$36,47940 claims
Astellas Pharma US IncMyrbetriq$297$20,88639 claims
GSKTrelegy Ellipta$1,742$17,67320 claims
PfizerEliquis$533$14,51918 claims
MerckJanuvia$236$13,50715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Trenton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →